BSE Live
Jan 16, 16:01Prev. Close
168.10
Open Price
166.75
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 16, 15:55Prev. Close
168.02
Open Price
168.40
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
166.28 (534)
| Key Financial Ratios of Piramal Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 5.22 | 3.05 | 0.58 | 2.91 | 9.11 | |
| Diluted EPS (Rs.) | 5.20 | 3.05 | 0.58 | 2.91 | 9.11 | |
| Cash EPS (Rs.) | 6.90 | 4.51 | 2.19 | 3.99 | 7.19 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 56.27 | 50.74 | 44.09 | 42.73 | 41.23 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 56.27 | 50.74 | 44.09 | 42.73 | 41.23 | |
| Dividend / Share(Rs.) | 0.14 | 0.11 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 39.91 | 33.18 | 28.85 | 26.10 | 29.55 | |
| PBDIT/Share (Rs.) | 9.42 | 6.20 | 3.68 | 5.24 | 8.21 | |
| PBIT/Share (Rs.) | 7.74 | 4.65 | 2.07 | 4.13 | 6.77 | |
| PBT/Share (Rs.) | 6.88 | 3.84 | 1.04 | 3.58 | 6.91 | |
| Net Profit/Share (Rs.) | 5.22 | 2.96 | 0.58 | 2.89 | 5.75 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 23.60 | 18.67 | 12.73 | 20.06 | 27.79 | |
| PBIT Margin (%) | 19.40 | 14.00 | 7.15 | 15.84 | 22.90 | |
| PBT Margin (%) | 17.23 | 11.56 | 3.59 | 13.70 | 23.36 | |
| Net Profit Margin (%) | 13.08 | 8.91 | 2.01 | 11.08 | 19.44 | |
| Return on Networth / Equity (%) | 9.27 | 5.82 | 1.32 | 6.76 | 13.93 | |
| Return on Capital Employed (%) | 12.68 | 8.39 | 4.04 | 8.61 | 15.71 | |
| Return on Assets (%) | 6.65 | 4.09 | 0.86 | 4.75 | 9.92 | |
| Total Debt/Equity (X) | 0.16 | 0.17 | 0.31 | 0.22 | 0.04 | |
| Asset Turnover Ratio (%) | 0.53 | 0.50 | 0.45 | 0.48 | 0.00 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.53 | 1.48 | 1.20 | 1.29 | 1.20 | |
| Quick Ratio (X) | 1.01 | 0.96 | 0.78 | 0.97 | 0.92 | |
| Inventory Turnover Ratio (X) | 4.48 | 1.57 | 1.79 | 2.23 | 0.00 | |
| Dividend Payout Ratio (NP) (%) | 2.09 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 1.58 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 97.91 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 98.42 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 30,775.75 | 17,962.99 | 9,729.01 | 0.00 | 0.00 | |
| EV/Net Operating Revenue (X) | 5.82 | 4.09 | 2.83 | 0.00 | 0.00 | |
| EV/EBITDA (X) | 24.66 | 21.91 | 22.18 | 0.00 | 0.00 | |
| MarketCap/Net Operating Revenue (X) | 5.62 | 3.88 | 2.37 | 0.00 | 0.00 | |
| Retention Ratios (%) | 97.90 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 3.99 | 2.54 | 1.55 | 0.00 | 0.00 | |
| Price/Net Operating Revenue | 5.63 | 3.88 | 2.37 | 0.00 | 0.00 | |
| Earnings Yield | 0.02 | 0.02 | 0.01 | 0.00 | 0.00 |
12.11.2025
Piramal Pharma Standalone September 2025 Net Sales at Rs 1,127.26 crore, down 12.23% Y-o-Y
06.11.2025
Piramal Pharma Consolidated September 2025 Net Sales at Rs 2,043.72 crore, down 8.83% Y-o-Y
05.11.2025
Piramal Pharma posts Rs 99 crore loss in Q2FY26 weighed down by CDMO business
29.07.2025
Piramal Pharma Consolidated June 2025 Net Sales at Rs 1,933.71 crore, down 0.89% Y-o-Y